Quantoom Biosciences is a pioneering startup established in 2021, headquartered in Belgium. The company is revolutionizing mRNA production through its innovative RNA Platform, Nfinity™, which integrates DNA (Nplify™) and RNA (Ntensify™) manufacturing and formulation (Ncapsulate™). Their comprehensive approach, inclusive of critical reagent supply, spans from sequence to large-scale production. The team, consisting of scientists, engineers, and clinicians, is dedicated to addressing the significant challenges in DNA and RNA production related to vaccines and therapeutics, thereby enhancing accessibility and autonomy in mRNA technology. Quantoom Biosciences benefits from the exceptional biotech ecosystem in Belgium and France, strategically positioning its facilities in the heart of Europe. Notably, Quantoom Biosciences is part of Univercells, a global life sciences Group committed to democratizing biologics. Currently, details regarding the last investment and the associated investors are not available for public disclosure.
There is no investment information
No recent news or press coverage available for Quantoom Biosciences.
We care about your data, and we'd love to use cookies make your experience better.
